Conditions: Metastatic Renal Cell Carcinoma (mRCC)
Keywords: Kidney cancer mRCC metastic renal cell carcinoma everolimus sunitinib pazopanib
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 29
Healthy volunteers: no

Brief summary:
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.

Detailed description:

Arms:
arm 1: Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.

Interventions: intervention 1: Everolimus (RAD001)
Intervention descriptions: intervention 1: Everolimus was used as commercially available formulated tablets of 10 mg strength

Protocol document: